Case Reports
Every UPC, EPO and national court decision our fee earners have written up — now filterable by the same 40+ tags they already use to classify each report, plus the court and industry sector behind it.
Reasonable expectation of success based on clinical trial disclosure: UPC Local Division takes a different view from EPO Board of Appeal
The UPC Munich Local Division invalidated Sanofi’s cabazitaxel patent, finding that Phase III clinical trial disclosures created a reasonable expectation of success—departing from the EPO’s earlier conclusion.
UPC court of appeal sets out comprehensive guidance on key substantive issues
The UPC Court of Appeal’s November 2025 decisions in Amgen v. Sanofi and Meril v. Edwards provide the most comprehensive guidance to date on inventive step, claim construction, sufficiency, added matter, and procedural rules. The Court clarified how the “objective problem” should be formulated, reinforced the need for a clear pointer or motivation for obviousness, and aligned many principles with established EPO and national case law. The judgments also address injunctions, proportionality, costs, competence, and amendment admissibility—making them essential reading for anyone navigating UPC litigation.
Court of Appeal gives Babek’s trade mark a gold star for validity
The Court of Appeal upheld the validity of Babek International Ltd’s trade mark after Iceland Foods Ltd challenged its registration. The judgment clarified that a trade mark must be a single, clearly and precisely represented sign capable of distinguishing goods or services. The court found that Babek’s mark met these requirements, rejecting arguments about lack of clarity and permissible variations. Iceland’s appeal was dismissed, affirming the trade mark’s validity and providing guidance on interpreting trade mark descriptions and representations.
Another day, another interim injunction granted by the UK High Court: Boehringer Ingelheim find success against Dr Reddy
Boehringer Ingelheim successfully obtained another interim injunction from the UK High Court against Dr Reddy, reinforcing its patent rights in ongoing pharmaceutical litigation. The article outlines the case details, the court’s reasoning, and what this decision means for patent enforcement in the UK.
Auxiliary claim requests inadmissible and indicative of likely invalidity in applications for provisional measures.
The UPC’s Munich Local Division denied Onward Medical’s bid for a preliminary injunction against Niche Biomedical, finding serious doubts over the novelty of the granted claim of EP 3 421 081 B1 in light of the Yoo prior art. The court also rejected all eight auxiliary claim requests, holding that amended claims cannot be used to establish likely validity in provisional‑measures proceedings. The decision reinforces that interim relief is only available for patents that appear robust in their granted form.
No Declaration of Non-Infringement for Alternative Product
The Unified Patent Court rejected Black Sheep’s request for a declaration of non-infringement (DNI) for an alternative product design. The court found the request inadmissible because HL Display had not asserted infringement against the alternative design, and Black Sheep had not formally sought acknowledgment of non-infringement before filing the counterclaim.
Apple Intervenes in Confidentiality Appeals: UPC Court of Appeal Allows Intervention in Ericsson and Sun Patent Trust Cases
Apple (Intervener) in Ericsson v. AsusTek and Apple (Intervener) in Sun Patent Trust v. Vivo UPC_CoA_631/2025[1], UPC_CoA_632/2025[2], UPC_CoA_755/2025[3], and UPC_CoA_757/2025[4] – Orders of 23...
UPC Infringement Actions: Is Speed Meeting Expectations?
The Unified Patent Court promised simplified and faster patent litigation across Europe. Two years in, we look at whether it’s delivering on that promise. For patent holders and defendants alike, the duration of infringement actions can significantly impact market strategies, investment decisions, and competitive positioning. In this article, we set out an in-depth analysis of how the court’s procedural rules are shaping the pace of litigation. By examining key milestones—from the filing of an infringement action to the issuance of a final judgment—we assess whether the UPC is delivering on its promise of efficiency.
Clear all filters
The UPC Newsletter
Get expert insights and the top patent stories delivered straight to your inbox.